This HTML5 document contains 12 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n5http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB05815/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05815/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05815
rdf:type
n3:Drug
n3:description
The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle". The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation.
n3:generalReferences
# Jacobs E, Watson SA, Michaeli D, Ellis IO, Robertson JF: Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts. Br J Cancer. 1999 May;80(3-4):352-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10408837
n3:group
investigational
n3:indication
Investigated for use/treatment in prostate cancer.
owl:sameAs
n5:DB05815
dcterms:title
GnRH pharmaccine
adms:identifier
n7:16132914 n9:DB05815
n3:mechanismOfAction
The immunological neutralization of Gonadotropin Releasing Hormone (GnRH) by the antibodies induced by GnRH pharmaccine shuts down the production of testosterone in the testes. Testosterone fuels prostate cancer, both early stage, primary cancer and metastatic (spreading) cancer. Like physical castration, hormonal, or biological blockage of testosterone has been shown to be efficacious in humans for the treatment of both early and late state prostate cancer. Aphton's GnRH pharmaccine, which is expected to be reversible based on the mechanism of action (in contrast to surgical castration), induces hormonal, or biological blockage of testosterone.
n3:Molecular-Formula
n8:271B4741-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B4740-363D-11E5-9242-09173F13E4C5